BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS BRIGHT GREEN CORPORATION BREAKS NEW GROUND IN DOMESTIC PHARMACEUTICAL PRODUCTION GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the...

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on...

MagicMed Industries to Present at the Q1 Virtual Investor Summit CALGARY, Alberta, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- MagicMed Industries Inc. ("MagicMed" or the "Company"), a biotechnology company focused on creating novel psychedelic...

InvestorBrandNetwork Introduces PsychedelicNewsWire – A Technology Driven Communications Platform Focused on Emerging Market Opportunities in all Aspects of Psychedelics and Therapeutics SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- (June 25, 2020) – via NetworkWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies...